At the 44th Annual JPMorgan Healthcare Conference, Novavax’s CEO John Jacobs emphasized the company’s renewed focus on expanding its late-stage pipeline beyond its flagship COVID-19 vaccine. Jacobs highlighted two Phase III studies: one evaluating a next-generation seasonal influenza nanoparticle vaccine and another assessing a combination respiratory vaccine targeting both influenza and RSV. He also reiterated Novavax’s goal of securing regulatory filings for these candidates by mid-2026, contingent on successful readouts. The presentation stressed disciplined cost management, with operating expenses projected to decline by approximately 20% year-over-year as the company transitions from pandemic-level manufacturing to sustainable commercial production.

Novavax shares experienced notable volatility in recent sessions, at one point declining more sharply than the broader healthcare sector before rebounding with a more than 10% uptick on above-average trading volume. Analysts attribute the initial pullback to profit-taking following a string of positive earnings revisions, while the subsequent surge appears driven by heightened institutional buying ahead of the company’s scheduled mid-year regulatory milestones. Trading activity in the last 10 sessions has averaged roughly 30% higher volume than the 60-day norm, signaling renewed investor interest in Novavax’s pipeline progress.